News & Views

  • Merger brings together Experts in Trial Design
    Yannis Jemiai
  • Dr Yuan Ji

Merger brings together Experts in Trial Design

Oct 15 2020 Read 276 Times

Drug development solutions company Laiya Consulting, specialising in Bayesian adaptive trial designs and implementation, has been acquired by Cytel Inc. The deal follows the recent release of Cytel’s East Alloy platform for easy access to verified Bayesian tools aimed at broadening industry access to innovative clinical trial design methods.

"As we look to make the benefits of sophisticated Bayesian methods ever more accessible to drug developers, we’re taking strategic leaps to both bolster our core offerings and streamline their delivery to the market," said Yannis Jemiai, Chief Scientific Officer at Cytel. "The release of East Alloy was a tremendous milestone here — effectively removing the daunting computational barriers to more widespread, easy Bayesian method implementation. Partnering with Laiya allows us to smoothly feed into our broad Bayesian software capabilities with ever greater levels of statistical innovation and expertise. We look forward to welcoming Dr Yuan Ji and his colleagues to the team."

Founded in 2010, Laiya pioneered the delivery of trial design software using SaaS, which aligns with Cytel’s goal of making all its design software available as a cloud-based service. Laiya’s co-founder Dr Yuan Ji is a Fellow of the American Statistical Association and a global authority on Bayesian statistics, having invented multiple Bayesian trial designs and authored more than 150 papers and book chapters on the topic.  He also jointly holds an appointment as Professor of Biostatistics at the University of Chicago.

"Bayesian approaches, when applied correctly, open an abundance of opportunity in clinical development, evidenced by our own and Cytel’s extensive work in this field," said Dr Yuan Ji, Co-founder of Laiya Consulting. "Merging with Cytel means unifying two rich sources of statistical proficiency to continue setting new standards for Bayesian design, which will ultimately help us to further enable drug developers to profitably solve the most intricate clinical challenges."

More information online 

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment





Digital Edition

Measurement Analysis China 2021 Buyers Guide

November 2020

The following Buyers’ Guide has been produced by International Labmate Ltd. International Labmate have been publishing magazines for over 46 years. We now publish 9 laboratory, environmental and...

View all digital editions

Events

Expomed Eurasia - NEW DATES

Nov 05 2020 Istanbul, Turkey

Pharma Asia - NEW DATES

Nov 10 2020 Karachi, Pakistan

JASIS 2020

Nov 11 2020 Chiba City, Japan

International Solid Waste Management Summit

Nov 12 2020 Shanghai, China

SETAC North America

Nov 15 2020 Virtual event

View all events